Skip to search formSkip to main contentSkip to account menu

Recormon

Known as: NeoRecormon 
National Institutes of Health

Related topics

Related topics

2 relations
Procrit

Broader (1)

epoetin beta

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Introduction to biological and small molecule drug research and development : theory and case studies
2012
2012
Hemoglobin Variability with Epoetin Beta and Continuous Erythropoietin Receptor Activator in Patients on Peritoneal Dialysis
♦ Background and Objectives: The extent to which hemoglobin (Hb) cycling occurs in peritoneal dialysis (PD) patients is unclear… 
Review
2012
Review
2012
Epoetin Beta
SummaryAbstractEpoetin beta (NeoRecormon®) is a recombinant form of erythropoietin. It increases reticulocyte counts, haemoglobin… 
2009
2009
Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label…
2006
2006
Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis.
BACKGROUND Anaemia is a common complication of chemotherapy (CT), including both non-platinum (Pt)-based as well as Pt-based CT… 
Review
2005
Review
2005
Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin α, epoetin β and darbepoetin α use in routine clinical practice
This retrospective observational survey assessed, in a routine clinical practice setting, the modalities of treatment with… 
2005
2005
Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer and radiochemotherapy
5121 Background: Patients with advanced cervical cancer frequently suffer from anaemia. Additionally, concomitant anaemia is… 
2004
2004
Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
BACKGROUND Severe anaemia is common in patients with metastatic, hormone-refractory prostate cancer (HRPC). PATIENTS AND… 
2003
2003
CREATE: new strategies for early anaemia management in renal insufficiency.
The ongoing Cardiovascular risk Reduction by Early Anaemia Treatment with Epoetin beta (CREATE) trial is investigating the effect… 
2002
2002
Two‐dimensional electrophoresis of recombinant human erythropoietin: A future method for the European Pharmacopoeia?
Quality assurance of recombinant protein drugs concerning identity and purity represents a difficult task, in particular, when… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)